Suyou Liu

Dr. Suyou Liu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZZZizheng Zou
Zizheng Zou
XHXiyuan Hu
Xiyuan Hu
TLTiao Luo
Tiao Luo
ZMZhengnan Ming
Zhengnan Ming
XCXiaodan Chen
Xiaodan Chen
ZLZhiyong Luo
Zhiyong Luo
Argininosuccinate synthase (ASS1) is a ubiquitous enzyme in mammals that catalyzes the formation of argininosuccinate from citrulline and aspartate. ASS1 genetic deficiency in patients leads to an autosomal recessive urea cycle disorder citrullinemia, while its somatic silence or down-regulation is very common in various human cancers. Here, we show that ASS1 functions as a tumor suppressor in breast cancer, and the pesticide spinosyn A (SPA) and its derivative LM-2I suppress breast tumor cell proliferation and growth by binding to and activating ASS1. The C13-C14 double bond in SPA and LM-2I while the Cys97 (C97) site in ASS1 are critical for the interaction between ASS1 and SPA or LM-2I. SPA and LM-2I treatment results in significant enhancement of ASS1 enzymatic activity in breast cancer cells, particularly in those cancer cells with low ASS1 expression, leading to reduced pyrimidine synthesis and consequently the inhibition of cancer cell proliferation. Thus, our results establish spinosyn A and its derivative LM-2I as potent ASS1 enzymatic activator and tumor inhibitor, which provides a therapeutic avenue for tumors with low ASS1 expression and for those non-tumor diseases caused by down-regulation of ASS1.

1 November 2018 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DMDa-You Ma
Da-You Ma
LWLong-Long Wang
Long-Long Wang
QLQin Lai
Qin Lai
KPKun-Jian Peng
Kun-Jian Peng
XLXuan Li
Xuan Li
SLSuyou Liu
Suyou Liu

1 November 2015 in Industrial Crops and Products
Verified
Journal Article
Closed access
SLSuyou Liu
Suyou Liu
FXFei Xu
Fei Xu
LLLijun Liu
Lijun Liu
DMDayou Ma
Dayou Ma

1 May 2020 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DMDa-You Ma
Da-You Ma
QLQin Lai
Qin Lai
KPKun-Jian Peng
Kun-Jian Peng
LWLong-Long Wang
Long-Long Wang
ZLZeng-Xia Li
Zeng-Xia Li
SLSuyou Liu
Suyou Liu

8 January 2026 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
XHXin-Yu Huang
Xin-Yu Huang
XLXiao-He Liu
Xiao-He Liu
NXNa Xu
Na Xu
TPTing Peng
Ting Peng
XHXi-Yuan Hu
Xi-Yuan Hu
DMDayou Ma
Dayou Ma

5 October 2017 in Synthetic Communications
Verified
Journal Article
Closed access
DMDa-You Ma
Da-You Ma
TZTao Zhong
Tao Zhong
LWLong-Long Wang
Long-Long Wang
LLLi-Jun Liu
Li-Jun Liu
YWYing-Xiong Wang
Ying-Xiong Wang
SLSuyou Liu
Suyou Liu
An efficient approach for integrin-targeting cRGDfK conjugate synthesis has been developed using a new protected cyclopentapeptide, cR(NO2)GD(Bn)fK(Fmoc), as the key intermediate. cR(NO2)GD(Bn)fK(Fmoc) was conveniently prepared in high yield. The Fmoc group of this cyclopentapeptide was selectively removed under mild conditions which makes it an ideal intermediate for cRGDfK conjugate synthesis as was well demonstrated in this paper by the synthesis of cRGDfK chlorambucil conjugate. GRAPHICAL ABSTRACT